N/A
N=391
Investigating Superion™ In Spinal Stenosis
Lumbar Spinal Stenosis · Intermittent Claudication
Bottom Line
View on ClinicalTrials.gov: NCT00692276 ↗Enrolled (actual)
391
Serious AEs
58.8%
Results posted
Aug 2020
Primary outcome: Primary: Percentage of Subjects With Clinically Significant Improvement in Outcomes — 52.7; 50.2 percentage of subjects
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Superion™ Interspinous Spacer (Device); X-STOP® IPD® Device (Device)
- Age
- Adult, Older Adult · 45+ yrs
- Sex
- All
- Sponsor
- Boston Scientific Corporation
- Primary completion
- Feb 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Subjects With Clinically Significant Improvement in Outcomes |
52.7; 50.2 | — |
Summary
The proposed prospective, multi-center, randomized clinical trial is designed to evaluate the safety and effectiveness of the Superion™ ISS compared to the X-STOP® IPD® device in healthy adults suffering from at least 6 months of moderate spinal stenosis symptoms who have been unresponsive to conservative care.
Eligibility Criteria
Inclusion Criteria
- Male or female subjects ≥ 45 years of age
- Persistent leg/buttock/groin pain, with or without back pain, that is relieved by flexion activities (example: sitting or bending over a shopping cart)
- Diagnosis of degenerative spinal stenosis of the lumbar spine, defined as the narrowing of the midline sagittal spinal canal (central) and/or narrowing between the facet superior articulating process (SAP), the posterior vertebral margin (lateral recess), and the nerve root canal (foraminal)
- Must be able to sit for 50 minutes without pain and to walk 50 feet or more
Exclusion Criteria
- Axial back pain only
- Fixed motor deficit
- Diagnosis of lumbar spinal stenosis which requires any direct neural decompression or surgical intervention other than those required to implant the control or experimental device
- Unremitting pain in any spinal position
- Significant peripheral neuropathy or acute denervation secondary to radiculopathy
- Lumbar spinal stenosis at more than two levels determined pre-operatively to require surgical intervention
- Significant instability of the lumbar spine as defined by 3mm translation or 5 degrees angulation
- Sustained pathologic fractures of the vertebrae or multiple fractures of the vertebrae and/or hips
- Spondylolisthesis or degenerative spondylolisthesis greater than grade 1.0 (on a scale of 1 to 4)
- Spondylolysis (pars fracture)
- Morbid obesity, defined as Body Mass Index (BMI) greater than 40kg/m2
- Insulin-dependent diabetes mellitus
- Prior surgery of the lumbar spine
- Cauda equina syndrome (defined as neural compression causing neurogenic bowel or bladder dysfunction)
- Infection in the disc or spine, past or present
- Paget's disease at involved segment or metastasis to the vertebra, osteomalacia, or other metabolic bone disease
- Tumor in the spine or a malignant tumor except for basal cell carcinoma
- Involved in pending litigation of the spine or worker's compensation related to the back
Data sourced from ClinicalTrials.gov (NCT00692276). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.